Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
14.1M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
602K
-
Shares change
-
+31.9K
-
Total reported value, excl. options
-
$1.06M
-
Value change
-
+$56.3K
-
Number of buys
-
8
-
Number of sells
-
-1
-
Price
-
$1.76
Significant Holders of Indaptus Therapeutics, Inc. - Common Stock (INDP) as of Q4 2023
18 filings reported holding INDP - Indaptus Therapeutics, Inc. - Common Stock as of Q4 2023.
Indaptus Therapeutics, Inc. - Common Stock (INDP) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 602K shares
of 14.1M outstanding shares and own 4.26% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (256K shares), INVESTMENT HOUSE LLC (102K shares), GEODE CAPITAL MANAGEMENT, LLC (54.8K shares), STRATEGY ASSET MANAGERS LLC (45.3K shares), Pine Valley Investments Ltd Liability Co (44.2K shares), RENAISSANCE TECHNOLOGIES LLC (29.4K shares), Vivaldi Capital Management LP (24K shares), STATE STREET CORP (19.5K shares), CITADEL ADVISORS LLC (16.5K shares), and Tower Research Capital LLC (TRC) (4.7K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.